Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESENT trial of Rikkunshito in functional dyspepsia from primary care
2024-515756-20-00Phase 3Authorised
- Sponsor
- UZ Leuven
- Start
- Jan 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in functional dyspepsia (FD) comparing Rikkunshito with Matching placebo granules (2 arms). Primary endpoint: Therapeutic effect on functional dyspepsia symptoms. Planned start Jan 2025; status: authorised.
02
Drugs
rikkunshito
03
Conditions
functional dyspepsia (FD)
Beyond the preview
Go deeper on 2024-515756-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515756-20-00.